Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Kwee Yong, Rakesh Popat et al.|British Journal of Haematology|2021Cited by 15
COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trialMarquita Camilleri, Kwee Yong, Jonathan Sive et al.|British Journal of Haematology|2020Cited by 7
OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)Rakesh Popat, Kwee Yong, William Wilson et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1
P-390 The differentiation and expansion of T cell clonotypes in the bone marrow following ASCT: insights from the Phase 2 CARDAMON studyKane Foster, Kwee Yong, Daria Galas‐Filipowicz et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0